


**HELLENIC  
ATHEROSCLEROSIS  
SOCIETY**



**TURKISH  
SOCIETY OF  
CARDIOLOGY**

**CO-ORGANIZATION**

**Hellenic Atherosclerosis Society - Turkish Society of Cardiology**



**PROGRAM**

# **Atherosclerosis International Meeting**

**07-09 September 2018**

**Athos Palace Hotel  
Chalkidiki, Greece**

# Friday, 7 September 2018

**11.00-11.45 Registrations**

**11.45-12.00 Introduction – Welcome Messages**

**L. Tokgozoglu, V. Kotsis**

**Atherosclerosis and cardiovascular risk update**

*Chair: A. Tselepis, H. Kultursay*

**12.00-12.30 Many faces of atherosclerotic vascular damage**

**N. Koylan**

**12.30-13.00 Imaging and Biomarkers: Are they really helpful?**

**N. Ozer**

**13.00-13.30 How do we determine risk in 2018?**

**E.B. Kaya**

**13.30-14.30 Light Lunch**

**14.30-15.30 Clinical workshop**

***Case presentations from the Turkish Cardiology Society***

*Chair: L. Tokgozoglu, M. Elisaf*

Interactive discussion with participants (4 cases 10 min each, followed by 5 min discussion)

**CVD epidemiology and prevention**

*Chair: V. Athyros, M. Kayikcioglu*

**15.30-16.00 Population aging and cardiovascular disease incidence: 60-years (1950s-2015) experience in Greece**

**D. Panagiotakos**

**16.00-16.30. Non-cardiac arterial disease and lipids**

**D. Mikhailidis**

**16.30-16.45 Coffee Break**

**Cardiovascular risk beyond LDL**

*Chair: N. Koylan, V. Kotsis*

**16.45-17.15 How important is non-HDL?**

**L. Tokgozoglu**

**17.15-17.45 Lp(a). Present and future**

**A. Tselepis**

**17.45-18.15 Nonalcoholic steatohepatitis: the emerging cardiovascular risk factor**

**V. Athyros**

**Dyslipidemias. New treatment options**

*Chair: D. Panagiotakos, N. Ozer*

**18.15-18.45 PCSK9 inhibitors in patients with familial hypercholesterolemia**

**M. Elisaf**

**18.45-19.15 How should we manage patients with high triglycerides?**

**M. Kayikcioglu**

# Saturday, 8 September 2018

## Treatment options and update on statin treatment

Chair: **M. Kayikcioglu, V. Kotsis**

09.00-09.30 How far should we lower LDL?

**H. Kultursay**

09.30-10.00 How should we treat patients with type II diabetes and dyslipidemia

**E. Liberopoulos**

10.00-10.30 Precision medicine in 2018 or What is new in prevention?

**D. Ural**

10.30-11.00 Statin intolerance

**K. Tziomalos**

11.00-11.30 **Coffee Break**

11.30-12.00 **Distinguished Lecture**

Chair: **A. Tselepis**

Shared risk factors for cardiovascular disease and dementia - genetic, epidemiologic, and causal aspects

**R. Frikke-Schmidt**

## Clinical workshop

12.00-13.00 **Case presentations from the Hellenic Atherosclerosis Society**

Chair: **E. Liberopoulos, D. Ural**

Interactive discussion with participants (5 cases 10 min each). (4 cases 10 min each followed by 5 min discussion)

## Treatment within co-morbidities: obesity, type II diabetes, hypertension and stroke

Chair: **K. Tziomalos, E.B. Kaya**

13.00-13.30 Drug combinations in the treatment of cardiovascular diseases

**V. Kotsis**

13.30-14.00 Treatment of diabetes in obesity

**N. Katsiki**

14.00-14.30 Treatment of hypertension and dyslipidemia in obesity

**V. Kotsis**

**Sunday, 9 September 2018**

**Clinical workshop**

**Case report presentations**

*Chair: K. Tziomalos, A. Tselepis*

- 09.00-09.30** Patient with hypertension and dyslipidemia  
**V. Kotsis**
- 10.00-10.30** Patient with CAD and LDLc 85 on atorvaatatin  
**M. Kayikcioglu**
- 10.30-11.00** Obese Patient with a stable angina and Tgs 210 mg/dL  
**K. Tziomalos**
- 11.00-11.30** Patient without treatment with obesity and LDL 210  
**V. Athyros**
- 11.30-12.00** Patient with hypertension, diabetes and LDL 145 mg/dL  
**N. Katsiki**
- 12.00-12.30** Patient with LDL 300mg/dL and family history of early CAD  
**L. Tokgozoglu**

## FACULTY

<b>Athyros V.</b>	Professor of Internal Medicine, School of Medicine, University of Thessaloniki, Greece
<b>Elisaf M.</b>	Professor of Internal Medicine, School of Medicine, University of Ioannina, Ioannina, Greece
<b>Frikke-Schmidt R.</b>	Chief Physician, Professor, Department of Clinical Biochemistry KB 3-01-1, Section for External Projects Rigshospitalet, Copenhagen University Hospital Copenhagen, Denmark
<b>Katsiki N.</b>	IASO/EASO Scope Member EASD Diabetes & Cardiovascular Disease Group Member Research Fellow of the 2nd Propedeutic Department of Internal Medicine, Hippokration University Hospital Thessaloniki, Greece
<b>Kaya E.B.</b>	Professor of Cardiology, School of Medicine, University of Hacettepe, Turkey
<b>Kayikcioglu M.</b>	Professor of Cardiology, School of Medicine, University of Ege, Turkey
<b>Kotsis V.</b>	Associate Professor of Internal Medicine School of Medicine, University of Thessaloniki, Greece
<b>Koylan N.</b>	Professor of Cardiology, School of Medicine, University of Istanbul Turkey
<b>Kultursay H.</b>	Professor of Cardiology, School of Medicine, University of Ege, Turkey
<b>Liberopoulos E.</b>	Associate Professor of Internal Medicine School of Medicine, University of Ioannina, Greece
<b>Mikhailidis D.</b>	Academic Head & Honorary Consultant, Department of Clinical Biochemistry, University College London, Royal Free Campus, London, UK
<b>Ozer N.</b>	Professor of Cardiology, Hacettepe University Faculty of Medicine Cardiology Department, Turkey
<b>Panagiotakos D.</b>	Professor of Biostatistics, Research Methodology and Epidemiology Department of Dietetics and Nutrition, Harokopion University, Athens, Greece
<b>Tokgozoglu L.</b>	Professor of Cardiology, School of Medicine, University of Hacettepe, Turkey
<b>Tselepis A.</b>	Professor of Clinical Biochemistry Department of Chemistry, Director of the Atherothrombosis Research Centre, University of Ioannina, Greece
<b>Tziomalos K.</b>	Assistant Professor of Internal Medicine School of Medicine, Aristotle University of Thessaloniki, Greece
<b>Ural D.</b>	Professor of Cardiology, School of Medicine, University of Koc, Turkey



1. ΟΝΟΜΑΣΙΑ ΤΟΥ ΦΑΡΜΑΚΕΥΤΙΚΟΥ ΠΡΟΪΟΝΤΟΣ PLATOREL 5 mg επικαλυμμένα με λεπτό υμένιο δισκία, PLATOREL 10 mg επικαλυμμένα με λεπτό υμένιο δισκία, PLATOREL 20 mg επικαλυμμένα με λεπτό υμένιο δισκία, PLATOREL 40 mg επικαλυμμένα με λεπτό υμένιο δισκία. 2. ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ Κάθε 5 mg δισκίο περιλαμβάνει 5 mg ροσουβαστατίνης ισοδύναμης με 5,2 ροσουβαστατίνης αβεσιούχου. Επίσης περιέχει 48,2 mg lactose monohydrate. Κάθε 10 mg δισκίο περιέχει 10 mg ροσουβαστατίνης ισοδύναμης με 10,4 ροσουβαστατίνης αβεσιούχου. Επίσης περιέχει 96,4 mg lactose monohydrate. Κάθε 20 mg δισκίο περιέχει 20 mg ροσουβαστατίνης ισοδύναμης με 20,8 ροσουβαστατίνης αβεσιούχου. Επίσης περιέχει 192,8 mg lactose monohydrate. Κάθε 40 mg δισκίο περιέχει 40 mg ροσουβαστατίνης ισοδύναμης με 41,7 ροσουβαστατίνης αβεσιούχου. Επίσης περιέχει 171,9 mg lactose monohydrate. Για τον πλήρη κατάλογο των εκδόχων, βλ. παράγραφο 6.1 της Περιλήψης Χαρακτηριστικών του Προϊόντος (ΠΧΠ).

Για συνταγογραφικές πληροφορίες συμβουλευτείτε την ΠΧΠ ή απευθυνθείτε στην εταιρεία ELPEN.



PLA/FPA/02-2018/03



# PLATOREL®

## Ροσουβαστατίνη



ELPEN Α.Ε. ΦΑΡΜΑΚΕΥΤΙΚΗ ΒΙΟΜΗΧΑΝΙΑ  
Λεωφ. Μαραθώνος 95, 190 09 Πικέρμι Αττικής,  
Τηλ.: 210 6039326-9, Fax: 210 6039300  
[www.elpen.gr](http://www.elpen.gr)

ΓΡΑΦΕΙΑ ΕΠΙΣΤΗΜΟΝΙΚΗΣ ΕΝΗΜΕΡΩΣΗΣ  
Σεβαστείας 11, 115 28 Αθήνα,  
Τηλ.: 210 7488711, Fax: 210 7488731  
Εθν. Αντιστάσεως 114, 551 34 Θεσσαλονίκη,  
Τηλ.: 2310 459920-1, Fax: 2310 459269

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την «ΚΙΤΡΙΝΗ ΚΑΡΤΑ»